Education
About Us
Working with TipRanks
Follow Us
PainReform (PRFX)
NASDAQ:PRFX
PRFX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.73 - $61.24
Previous CloseN/A
Volume49.01K
Average Volume (3M)1.53M
Market Cap
$4.18M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.33M
Total Debt (Recent Filing)$72.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
May 20, 2025EPS Estimate
-7.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.29
Shares Outstanding1,706,232
10 Day Avg. Volume36,980
30 Day Avg. Volume1,532,758
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
---
PainReform News
PremiumCompany Announcements
PainReform Expands into Clean Energy with DeepSolar Acquisition
PremiumCompany Announcements
PainReform Announces Extraordinary General Meeting to Discuss Key Proposals
PremiumCompany Announcements
PainReform Ltd. Expands Share Offering to $4 Million
PremiumCompany Announcements
PainReform Diversifies with Acquisition of AI Solar Platform DeepSolar
PremiumCompany Announcements
PainReform Ltd. Gains $3.17 Million from Warrant Exercise
PremiumCompany Announcements
PainReform Faces Setback in Phase 3 Trial for PRF-110---
Bulls Say, Bears Say
Bulls Say
Product EfficacyPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial ResourcesPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
---
Ownership Overview
―
Insiders
0.22%
Mutual Funds
0.76% Other Institutional Investors
99.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.73 and its highest was $61.24 in the past 12 months.
What is PainReform’s market cap?
PainReform’s market cap is $4.18M.
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is May 20, 2025 which is in 51 days.
How were PainReform’s earnings last quarter?
Currently, no data Available
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate is -7.68.
How many shares outstanding does PainReform have?
PainReform has 1,706,232 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
---
Company Description
PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
---
PRFX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---